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Abstract
Objectives
Childhood-onset systemic lupus erythematosus (cSLE) presents with diverse clinical features and often with non-classical 
symptoms that may delay diagnosis and increase risk of morbidity and mortality. This paper aims to analyse incidence, 
and clinical and laboratory features of cSLE in Croatia between 1991 and 2010, and to identify factors inﬂuencing time 
to diagnosis.
Results
Medical records at three university-based tertiary care centres were analysed retrospectively for 81 children with cSLE 
(68 girls). Mean age at onset was 13.4±2.8 yr (interquartile range 3), and annual incidence varied from 1–15 per million 
at risk. The most frequent clinical and laboratory features were musculoskeletal symptoms (80%) and increased erythrocyte 
sedimentation rate (96%). The most frequent immunological laboratory ﬁndings were the presence of antibodies against 
histones (86%), double-stranded DNA (73%), and Sm protein (64%), as well as low levels of C3 complement (69%). 
Haematuria was present in 58% of children, proteinuria in 56%, and biopsy-conﬁrmed lupus nephritis in 43%. 
Median time from symptom onset to diagnosis was 2 months (range 0–96). Time to diagnosis was inversely associated 
with ECLAM score (p<0.001), but it showed no association with age, gender, clinical features or distance from the nearest 
paediatric centre.
Conclusion
This is the ﬁrst large-scale, in-depth study of clinical and laboratory features of cSLE in Croatia. Among all demographic, 
laboratory and clinical features examined, ECLAM score alone was inversely associated with time to diagnosis. This 
highlights the need to improve detection of children with fewer symptoms early in the course of the disease, therefore 
serious consequences for prognosis could be avoided.
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Introduction
Systemic lupus erythematosus (SLE) is 
a chronic autoimmune disease caused 
by changes in the immune system that 
lead to inﬂammation of blood vessels 
and connective tissue in all organs and 
systems; therefore, SLE presents with 
a broad spectrum of clinical features, 
along with abnormal laboratory values 
(1).
SLE usually occurs in young women 
(female to male ratio 7–15:1), but 
in as many as 20% of cases, the ﬁrst 
symptoms appear in children and ado-
lescents under 18, in a form known as 
childhood-onset systemic lupus ery-
thematosus (cSLE) (1-4). Most chil-
dren who suffer from cSLE develop 
symptoms during puberty, and disease 
onset before the age of ﬁve years is 
rare (1). The prevalence of cSLE is ap-
proximately 4- to 6-fold higher among 
girls, and it is estimated at 6.4–50 per 
100.000 (1, 5), while the annual inci-
dence rate varies between 2.2 to 9 per 
million (5-7).
The ﬁrst manifestations of cSLE can be 
quite diverse and usually include one or 
more of the following: fever, malar or 
discoid rash, polyarthralgia and arthri-
tis (1, 3, 9). This chronic and systemic 
illness often leads to serious compli-
cations, including musculoskeletal, 
neuropsychiatric and renal problems. 
Cumulative organ damage occurs in up 
to 60% of patients, which signiﬁcantly 
reduces quality of life (10, 11). Indeed, 
the initial symptoms and course of the 
disease are more severe than in adults, 
often necessitating more aggressive 
treatment (12, 13). Diagnosis of cSLE 
is made on the basis of clinical features 
and laboratory ﬁndings, but the diver-
sity of cSLE symptoms and its often 
non-classical and misleading presenta-
tion (e.g. other than skin, joints, consti-
tutional symptoms) can extend time to 
diagnosis and treatment considerably 
(8). Even though such delays are the 
single most important factor inﬂuenc-
ing morbidity and mortality in children 
with cSLE (14, 15), factors inﬂuencing 
time from symptom onset to diagnosis 
are rarely investigated.
Although the exact mechanisms and 
pathophysiology of cSLE remain un-
clear, environmental factors are known 
to trigger the disease in genetically 
and hormonally predisposed individu-
als. While some environmental factors 
such as viruses remain controversial, 
others are well substantiated, including 
several drugs and ultraviolet-B (UV-B) 
radiation (1). Despite of that, we are 
unaware of studies investigating possi-
ble differences in SLE features within 
a population with respect to differences 
in climate or solar irradiation in differ-
ent parts of the same country, since the 
studies on (c)SLE involve the entire 
population of a particular country.
In the present study, we performed a 
20-year retrospective analysis to es-
tablish incidence of cSLE in Croatia. 
We investigated clinical and labora-
tory features of children with cSLE in 
Croatia, and compared patients from 
parts of the country receiving differ-
ent amounts of solar radiation in or-
der to explore possible differences in 
cSLE features. Also, we investigated 
time form symptom onset and cSLE 
diagnosis, and examined numerous de-
mographic, clinical and laboratory fea-
tures of these cases to identify factors 
inﬂuencing time to diagnosis.
Patients and methods
The protocol for this retrospective 
study was approved by the ethics com-
mittees of all three participating hos-
pitals (University Hospital Centre Ri-
jeka, University Hospital Centre Split, 
University Hospital Centre Zagreb), as 
well as by the ethics committee of the 
University of Zagreb School of Medi-
cine.
We reviewed medical records of all pa-
tients aged ≤18 years at disease onset 
who were diagnosed with cSLE during 
the period 1991–2010 in the paediat-
ric departments of three university-af-
ﬁliated tertiary care hospitals in the 
three largest cities in Croatia, namely 
Zagreb, Rijeka, and Split. The diagno-
sis of cSLE was made on clinical and 
immunological grounds, and in order  
to be included in this study, patients 
needed to fulﬁll the 1997 ACR criteria 
for the classiﬁcation of SLE (9). The 
patients with overlap syndrome were 
not included in this study.
All children were admitted to one of 
these three hospitals after being re-
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ferred by a primary care practitioner 
or a physician at a local secondary care 
hospital for suspected cSLE, or simply 
for “fever of unknown cause”, “arthral-
gia/arthritis” or “rash”. In the Croatian 
health care system, referring physicians 
usually suspect cSLE, but do not make 
the ﬁnal paediatric rheumatology diag-
nosis or initiate treatment. Instead, pa-
tients presenting with uncertain or seri-
ous diagnoses are referred to a hospital, 
which may be one of the three tertiary 
care centres in this study in the case of 
patients living in or near Split, Zagreb, 
or Rijeka, or it may be a secondary 
care centre in the case of patients liv-
ing outside the three cities examined 
here – these patients were subsequent-
ly referred to one of the three tertiary 
centres involved in this study. Thus, all 
patients suspected for cSLE in Croatia 
were eventually referred, admitted to 
and evaluated in one of the tertiary care 
centres involved in this study.
Although several co-authors retrieved 
and prepared medical documentation 
of patients with cSLE from the archives 
of three tertiary care hospitals involved 
in this study, and different paediatric 
departments, only one author reviewed 
the medical documentation of each pa-
tient and did the actual data collection, 
while the decision about the recruit-
ment of the patients in the study was 
made by the paediatrician with 10-year 
experience in paediatric rheumatology.
Clinical presentation was deﬁned as all 
symptoms and signs were (a) reported 
by the child or the parents at disease on-
set; (b) observed by physicians during 
examinations in the primary, secondary 
or tertiary care centres; and (c) present 
at the time of diagnosis in the tertiary 
care referral centre. Time to diagnosis 
was deﬁned as the interval between the 
time of onset of the ﬁrst cSLE symp-
toms and the time when cSLE diagno-
sis was established in one of the three 
referral hospitals.
cSLE activity at the ﬁrst in-hospital 
evaluation in the tertiary referral centre 
was manually calculated according to 
the European Consensus Lupus Activ-
ity Measurement (ECLAM) index (16), 
which has been validated for retrospec-
tive analysis of disease activity (17). 
The medical records of all children in 
the study were complete enough to pro-
vide all laboratory data for calculating 
the ECLAM score. These included data 
on proteinuria, haematuria and urinary 
casts, erythrocyte sedimentation rate 
(ESR), serum creatinine levels, num-
bers of erythrocytes, leukocytes and 
thrombocytes, concentration of C3 
complement, and total complement ac-
tivity (CH50).
Annual incidence of cSLE was calcu-
lated over the entire study period based 
on population data for the population 
at risk (5–18 years of age) provided by 
the Croatian Bureau of Statistics (per-
sonal communication).
Laboratory ﬁndings
Relevant laboratory ﬁndings were de-
ﬁned to be those present a) at the ﬁrst 
in-hospital evaluation of the child in 
one of the tertiary care referral cen-
tres and b) at the time of diagnosis in 
the referral centre. These ﬁndings in-
cluded: erythrocyte sedimentation rate, 
numbers of erythrocytes, leukocytes, 
and thrombocytes, proteinuria (>0.5 
g/24 h), haematuria (>5 red blood cells 
(RBC) seen per high power ﬁeld, HPF), 
increased serum creatitine (>80 mmol/
L), low concentrations of complement 
C3 (<0.9 g/L), complement C4 (<0.1 
g/L), and rheumatoid factor (RF >14 
IU/mL).
ANA were determined by indirect im-
munoﬂuorescence (IIF) using com-
mercially available slides of HEp-2 
cells (Euroimmun, Lubeck, Germany). 
Patients sera were diluted 1:100 for 
screening. All positive samples were 
titrated in doubling dilutions until end 
point. Results were reported as nega-
tive (<1:100) or positive (expressed 
as a antibody titer). Starting in 2004, 
all positive ANA sera by IIF were fur-
ther tested by antigen-speciﬁc ELISA 
(Euroimmun, Lubeck, Germany) or by 
AtheNA Multi-Lyte ANA-test system, 
a multiplexed, microparticle Luminex-
based immunoassay (Zeus Scientiﬁc 
Inc, New Jersey, USA) that allows for 
the simultaneous detection of 9 antibod-
ies of established clinical signiﬁcance 
(antibodies to dsDNA, histone, SS-A, 
SS-B, Sm, RNP, Scl-70, Jo-1 and cen-
tromere B). The results were expressed 
in international units. Samples were 
considered positive when values were 
greater than 20 IU/ml (for ELISA) and 
greater than 120 IU/ml (for Luminex).
ELISA tests for anti-aCL IgG, and anti-
aCL IgM were purchased from Hycor 
Biomedical Inc (Garden Grove, USA), 
and speciﬁc enzyme labelled anti-IgG 
and anti-IgM conjugate were used. Sera 
were considered to be positive for anti-
aCl IgG when values were greater than 
40 U/ml, and for anti-aCl IgM when 
values were greater than 30 U/ml.
Lupus anticoagulant (LAC) was de-
tected by coagulation assays including 
prothrombin time, an activated partial 
tromboplastin time and dilute Russell s 
viper venom time.
Presence of lupus nephritis was evalu-
ated by pathohistological examination 
of biopsied renal tissue by light and 
electron microscopy, as well as by im-
munoﬂuorescence to label IgA, IgG, 
IgM, C3 and C1q. Renal biopsy was 
performed on the bases of clinical and 
laboratory indication, as well as in all 
children with proteinuria >0.8 g/day. 
The slides were examined by experi-
enced pathologists, and lupus nephritis 
was classiﬁed according to pre-2004 
standards of the World Health Or-
ganisation (WHO) (18) and post-2004 
standards of the International Society 
of Nephrology (ISN) (19), using the 
following typology (WHO/ISN): type 
2, pure mesangial alterations/mesang-
ial proliferative lupus nephritis; type 
3, focal segmental glomerulonephri-
tis/focal lupus nephritis; type 4, dif-
fuse glomerulonephritis/diffuse lupus 
nephritis; type 5, diffuse membranous 
glomerulonephritis/membranous lupus 
nephritis; and type 6, advanced scleros-
ing glomerulonephritis/advanced scle-
rosing lupus nephritis.
Subgroup analysis by sunlight 
exposure 
We divided our study population into 
subgroups by sunlight exposure in 
order to determine whether such ex-
posure was associated with particular 
clinical or laboratory features of cSLE. 
Using a solar irradiation map from the 
Croatian Meteorological and Hydrolog-
ical Service (20), children were divided 
into two groups depending on whether 
they lived in a continental climate, 
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which received annual solar energy of 
3161–4680 MJ/m2, or a Mediterranean 
climate, which received annual solar 
energy of 4681–5760 MJ/m2.
Statistical analysis
Demographic, clinical and laboratory 
features were summarised using descrip-
tive statistics. Differences in clinical 
and laboratory features were analysed 
by Fisher’s exact test and the χ2-test. 
Categorical variables were compared 
using Fisher’s exact test, while continu-
ous variables were compared using the 
t-test for independent samples. Asso-
ciations between continuous variables 
were assessed using the rank correla-
tion test (Spearman’s correlation test). 
All statistical analyses were performed 
using MedCalc 9.5.1.0 (MedCalc Soft-
ware, Mariakerke, Belgium).
Results
Patients
During the 20-year study period, 81 
children (68 girls, 84%) met our in-
clusion criteria. Mean age (±SD) at 
the disease onset was 13.4±2.8 yr for 
both genders, 13.6±2.7 for girls (range 
6–17), and 12.3±3.1 for boys (range 
7–18). There were 15 children aged be-
tween 6–11 yrs, 64 between 12–17 yrs, 
and 2 aged 18 yrs (interequartile range 
3 yrs).
The median time from symptom onset 
to diagnosis was 2 months (range 0–96 
months). In 9 children (11%), time to 
diagnosis was longer than 1yr, in 1 
child (1.2%) it was 2 yr, and in another 
child it was 8 yr.
One girl aged 10 yr at symptom onset 
was diagnosed with cSLE and was pos-
itive for antinuclear antibodies. At the 
time of diagnosis, the girl was being 
treated with carbamazepine for epilep-
sy, and cSLE symptoms and laboratory 
ﬁndings resolved after she was taken 
off carbamazepine; therefore she was 
excluded from the study.
Epidemiology
In this study of a predominantly Cau-
casian population, the ratio of females 
to males was 5.2:1. The overall annual 
incidence rate varied from 1 to 15 per 
million at risk (Fig. 1). Annual inci-
dence rates among boys ranged from 0 
to 7 per million at risk, while annual 
incidence rates in girls ranged from 2 
to 23 per million at risk, with several 
peaks (Fig. 1). Starting from year 2004, 
annual incidence rates were signiﬁcant-
ly higher than before 2004 (p=0.019, 
t-test for independent samples) (Fig. 
1). Among our 81 patients, 3 (3.7%) 
had a ﬁrst-degree relative with SLE. 
One boy had both his mother and sister 
who developed SLE as adults, and two 
girls were twins from the same family. 
Clinical and laboratory manifestations 
of children with positive family history 
did not differ from those in children 
with negative family history.
Clinical features prior to referral
Most of the children complained of ar-
thropathia/arthritis (54%), rash (35%), 
and general symptoms including fever, 
malaise and weight loss (36%). One-
ﬁfth was referred due to abnormal lab-
oratory ﬁndings, including increased 
ESR, cytopenia, haematuria, and pro-
teinuria. Small numbers of children 
were referred because of headache 
(n=3), abdominal pain (4), lymphad-
enopathy (11), Raynaud’s phenomenon 
(9), and oedema (3).
Prior to referral, children had a median 
of 1 symptom (range 1–4): 53% had one 
symptom, 31% two symptoms; 11% 3 
Fig. 1. Annual incidence rates of juvenile systemic lupus erythematosus among Croatian children, 1991–2010.
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symptoms; and 5% 4 symptoms. Most 
of the children with one complaint had 
musculoskeletal (n=18), skin (n=11), or 
constitutional (n=6) symptom; children 
with 2 complaints had musculoskeletal 
symptom combined with constitutional 
(n=9), or skin (n=5) symptom; while 
children with 3 symptoms mostly had 
musculoskeletal and constitutional 
symptoms combined with skin (n=3) or 
laboratory (n=2) symptom. Of the chil-
dren with 4 symptoms, one had a com-
bination of musculoskeletal, constitu-
tional, renal and laboratory symptoms, 
another a combination of musculoskel-
etal, skin, renal and immunological 
symptoms, while two had musculoskel-
etal, constitutional and skin symptoms 
combined with neurological or renal 
symptom (1 of each).
Clinical features at diagnosis
The most frequent initial symptoms 
at the time of diagnosis were mus-
culoskeletal, occurring in 80% of chil-
dren, followed by skin and mucosa 
involvement (65%) and constitutional 
symptoms (62%) (Table I). The least 
frequent initial symptoms were respi-
ratory (4%). Symptoms and signs did 
not differ signiﬁcantly between girls 
and boys, except that skin and mucosa 
involvement was more frequent among 
boys (90% vs. 62%, p=0.028).
Of the 65 children with musculoskel-
etal symptoms, 55 (85%) showed 
joint involvement, while 42 (79%) of 
53 children with skin and mucosa in-
volvement presented with malar rash. 
Additionaly, less frequent symptoms 
included abdominal, cardiovascular, 
and neuropsychiatric involvement, as 
well as immunological abnormalities 
(splenomegaly, lymphadenopathy, and 
antiphospholipid syndrome and hyper-
coagulability characterised with deep 
vein thrombosis, microvascular throm-
bosis in renal, skin and pulmonary ves-
sels, and positive LAC and anti-CL 
IgG antibodies).
During the ﬁrst in-hospital evaluation 
in the tertiary referral centre, the mean 
number of affected organ systems 
was 4 (range 1–7). The two genders 
were similar in the number of organs 
(p=0.061) and in which organs were af-
fected (p>0.175), except that boys had 
more heart symptoms (p=0.003). The 
mean ECLAM score was 5.1 (SD 2.4, 
median 5, range 1–10). ECLAM score 
did not vary signiﬁcantly with gender 
(p=0.962) or age (p=0.850 using a 
cut-off of 14 yr). Of the 81 children, 
10 (12%) presented with non-classi-
cal symptoms, including torticolis, 
oedemas in various locations, chorea 
with ataxia, dysarthria and dysphonia, 
icterus, and sepsis. Small numbers of 
children had serious conditions as part 
of the onset of cSLE symptoms: lupus 
encephalitis (n=2), tetraparesis (1), sei-
zures (2), antiphospholipid syndrome 
and hypercoagulability (3), hyperten-
sion (2), cardiomyopathy (1), growth 
retardation (1), and osteoporosis (2).
More than one-third of the children (28 
girls, and 3 boys) had other co-morbid-
ity (e.g. organ involvement/conditions 
usually not associated to cSLE), such as 
IgA hypoglobulinemia (n=6), autoim-
mune thyroiditis (n=9), autoimmune 
hepatitis (n=5), juvenile idiopathic 
arthritis (enthesitis-related arthri-
tis, HLA-B27+ [2]), hyperinsulinism 
(n=1), Sjögren disease (n=1), celiac 
disease (n=1), thoracic scoliosis (n=1), 
pollen allergy (n=1), seborrhea (n=1), 
gigantismus (n=1), obesity (n=1), and 
knee tumour (n=1). There was no dif-
ference in the occurrence of other con-
ditions between genders (p=0.206).
Laboratory features
The most frequent abnormal ﬁnd-
ing was increased ESR, present in 74 
of 77 tested children (96%) (Table I). 
Nearly half (43%) of 78 tested chil-
dren had anaemia, which was more 
frequent in boys than in girls (69% vs. 
40%, p=0.029, χ2 test). Similarly, leu-
kopenia was signiﬁcantly more com-
mon in boys (46% vs. 20%, p=0.017, 
Table I. Clinical and laboratory signs during the ﬁrst in-hospital evaluation in the tertiary referral centre of 81 Croatian children with 
cSLE. 
Signs (n)*
Clinical symptoms % of tested Laboratory features % of tested Antibodies % of tested
Musculoskeletal (81) 80 Accelerated ESR (77) 96 Anti-nuclear (79) 95
Skin and mucose (81) 65† Low C3 complement (70) 69 Anti-histones (21) 86
Constitutional (81) 62 Low C4 complement (70) 44 Anti-dsDNA (37) 73
   Fever (81) 31 Hematuria (81) 58 Anti-Sm (33) 64
   Fatigue (81) 26 Proteinuria (81) 56‡  Anti-RNP (27) 48
   Malar rash (81) 52 Anaemia (78) 43§ Anti-SS-A (Ro) (29) 35
Renal (81) 58 Thrompocytopenia (76) 31 Anti-Scl-70 (19) 32
Immunological** (81) 26 Leukopenia (78) 22†† Anti-SS-B (La) (29) 23
Abdominal (81) 22 Pancytopenia (76) 15 Anti-Jo-1 (21) 19
Cardiovascular (81) 20 Elevated serum creatinine (81) 20 Anticardiolipin
Vascular (81) 15       IgG (41) 32
   Raynaud’s phenomenon (81) 14       IgM (41) 29
Neuropsychiatric (81) 7   LAC (41) 20
Respiratory (81) 4
ESR: erythrocyte sedimentation rate, LAC: lupus anticoagulant, RF: rheumatoid factor.
*Number of tested children; †Girls (62%) vs. boys (90%), p=0.028, Fisher’s exact test; ‡Girls (32 %) vs. boys (69 %), p=0.025, Fisher’s exact test; §Girls 
(40%) vs. boys (69%), p=0.029, χ2 test; **Splenomegaly, lymphadenopathy, antiphospholipid syndrome and hypercoagulability characterised with deep vein 
thrombosis, microvascular thrombosis in renal, skin and pulmonary vessels, and positive LAC and anti-CL IgG antibodies; ††Girls (20%) vs. boys (46%), 
p=0.017, χ2 test.
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χ2-test). Of children with anaemia, 6 
had antibodies against erythrocytes, of 
children with leukopenia or thrombo-
cytopenia only 2 had antibodies against 
leukocytes or thrombocytes, while of 
children with pancytopenia only 1 had 
antibodies against all three blood cells.
Different types of cytopenias did not 
show any association with the presence 
of antibodies against erythrocytes, leu-
kocytes, or thrombocyte, or with hepa-
to- or splenomegaly.
Hypocomplementemia was frequent: 
out of 70 tested children, 69% had 
low concentrations of complement C3, 
while 44% had low concentrations of 
complement C4 (Table I). Lupus anti-
coagulant antibody was present in 20% 
of 41 tested children, and 31% of 64 
tested children had increased RF levels 
(Table I). The concentration of anti-CL 
IgG antibody was very high (>40 U/
mL) in 13 of 41 (32%) tested children, 
while concentration of anti-CL IgM an-
tibody was very high (>30 U/mL) in 12 
of 41 (29%) patients (Table I).
Of 79 children, 95% were positive by 
the ANA screen, with a median titer of 
1:1 280 (range1:20 to 1:20480). The 
anti-nuclear antibodies most frequently 
present were against histones (18 of 21 
children, 86%) and dsDNA (27 of 37, 
73%); the anti-nuclear antibody least 
frequently found was against Jo-1 (4 of 
21 children, 19%) (Table I).
Renal involvement
Kidneys were affected in 47 of 81 chil-
dren (58%), which usually manifested 
as haematuria (47 of 81, 58%) and pro-
teinuria (>0.5 g/24 h, 45 of 81, 56%) 
(Table II). Renal symptoms occurred 
equally frequently in girls and boys, 
except for proteinuria, which was twice 
as frequent in boys (9 of 13, 69%) than 
in girls (22 of 68, 32%, p=0.025).
On the basis of clinical and laboratory 
indications renal biopsy was performed 
in 35 of 81 patients (43%): pathohisto-
logical examination revealed type 2–6 
glomerulonephritis in all cases. The 
most frequent types of glomerulone-
phritis were types 3 and 4 in girls (9 
and 7 of 29, respectively) and types 4 
and 5 in boys (2 and 2 of 6, respective-
ly, Table II).
Two children had suffered renal fail-
ure by the time of the ﬁrst in-hospital 
evaluation in the tertiary referral cen-
tre, and one had to be dialysed.
Treatment and outcome
The ﬁrst in-hospital evaluation in the 
tertiary referral centre lasted a median 
of 66 days (range 11–146). Before the 
year 2004, none of 29 children stayed in 
hospital for less than a month, 4 (14%) 
stayed between 30–60 days, 9 (31%) 
between 60–90 days, while 16 (55%) 
children stayed in hospital more than 
3 months (median 99, range 37–132 
days). In 2004 and after, the admission 
time was signiﬁcantly shorter compared 
to admission time before 2004 (median 
54, range 11–146 days, p<0.001, t-test 
for independent samples): 17 (33%) 
children stayed in the hospital for less 
than a month, 21 (40%) between 30–60 
days, 10 (19%) between 60–90 days, 
and 4 (8%) more than 90 days.
Of 81 children in this study, 79 were 
discharged as being in “improved 
condition/remission”. Five girls were 
transferred to other paediatric wards, 
namely cardiology (n=2), dialysis 
(n=2), and nephrology (n=1). After the 
ﬁrst in-hospital evaluation, 6 children 
were re-admitted because of relapses: 1 
boy and 5 girls had relapse after a me-
dian of 12 months (range 4–48), while 
another girl relapsed more than 5 times 
in the next two years.
The children received treatment after 
the clinical assessment and after the 
blood and urine samples were taken for 
the laboratory evaluation in the tertiary 
referral centre.
Most children were treated with glu-
cocorticoids (methylprednisolone or 
prednisone, 73%), azathioprine (27%), 
cyclophosphamide (24%), hydroxy-
chloroquine (21%)¸ non-steroidal anti-
inﬂammatory drugs (NSAIDs, 19%), or 
combinations of these. In some cases, 
one or more of these drugs was used in 
combination with other immunomodu-
latory agents: methotrexate (n=4), hu-
man immunoglobulins (4), mycopheno-
late mofetil (2), or chimeric monoclonal 
antibody against CD20 protein (2).
Of the total group of 81 children, 13 
(16%) needed additional therapy, such 
as transfusion (erythrocytes [n=5], 
platelets [n=1], albumins [n=1]), plas-
mapheresis (n=1), pericardiocentesis 
(n=2), or dialysis (n=3). Less than 4 
children required physical therapy to 
correct already impaired limb function 
caused by arthralgia/arthritis or con-
tractures.
During the ﬁrst in-hospital evaluation 
in the tertiary referral centre, 2 of 13 
boys died, corresponding to 15% of 
the boys in the study and 3% of the 
entire study population. One boy died 
28 days after the admission because 
of catastrophic antiphospholipid syn-
drome. His ﬁrst symptoms included 
arthralgia/arthritis and recurrent fe-
ver, but during the next 2 months and 
prior the admission in tertiary referral 
centre, and developed CNS vasculi-
tis with chorea, ataxia, disarthria, and 
dysphonia, along with aggresive mi-
crovascular occlusive disease, charac-
terised with microvascular thrombosis 
in renal, skin and pulmonary vessels; 
ANA titre was 1:8192, concentration of 
anti-dsDNA 268 IU/mL, RF 48 IU/mL, 
Table II. Renal signs during the ﬁrst in-hospital evaluation in the tertiary referral centre of 
81 Croatian children with cSLE. 
Signs (n)*
Clinical symptoms % of tested Pathohistological ﬁnding % of tested
Renal (81) 58 Glomerulonephritis (81)† 43
Haematuria (81) 58 Type 2 (35) 9
Proteinuria (81) 56‡ Type 3 (35) 28
Elevated serum creatinine (81) 20 Type 4 (35) 26
Oedema (81) 11 Type 5 (35) 20
Hypertension (81) 4 Type 6 (35) 17
Nephritic syndrome (81) 2
Nephrotic syndrome (81) 1
Renal failure (81) 2
*Number of tested children; †Renal biopsy was performed on the basis of clinical and laboratory indi-
cations; ‡‡Girls (32 %) vs. boys (69 %), p=0.025, Fisher’s exact test.
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complement C3 0.35 IU/mL, and anti-
CL IgG 35 U/mL.
The other boy died of renal failure. He 
presented with a 2-week history of ar-
thralgia/arthritis and fatigue prior the 
ﬁrst in-hospital evaluation in tertiary 
referral centre, but during his stay in 
hospital he developed acute renal fail-
ure, with the concentration of antibod-
ies against SS-A 724I U/mL, SS-B 780 
U/mL, Sm 412U/mL, RNP 282 U/mL, 
dsDNA 95, both CL IgM and IgG 11 
U/mL, and complement C3 0.5g/L, 
and C4 0.05 g/L. Because there was no 
transplant option, he was treated with 
dialysis, but he died 52 days after the 
admission.
Relationship of clinical and 
laboratory features with the presence 
of auto-antibodies and C3 and C4 
complement levels
Elevated concentrations of at least one 
autoantibody and/or low complement 
were associated with symptoms affect-
ing skin and mucosa, the nervous or 
abdominal systems, and kidneys (Ta-
ble III). Anti-SS-B, anti-RNP, anti-CL 
IgM, and anti-CL IgG were not asso-
ciated with any of clinical symptoms, 
patients’ gender or their location.
Girls and boys showed similar distribu-
tions of autoantibodies.
Inﬂuence of annual solar irradiation 
on the clinical and laboratory 
presentation of cSLE
In order to explore whether sunlight 
exposure affects clinical and laboratory 
features of cSLE, we divided patients 
into two subgroups based on their resi-
dence: the continental subgroup (n=46) 
received lower annual solar irradiation, 
while the Mediterranean subgroup 
(n=35) received higher annual solar 
irradiation. The two subgroups were 
comparable in size (p=0.267), age 
(p=0.103), and gender (p=0.135).
The two subgroups did not differ in EC-
LAM score (p=0.955) or in clinical or 
laboratory presentation of cSLE (Table 
III). However, the Mediterrean subgroup 
showed signiﬁcantly higher frequencies 
of several anti-nuclear antibodies: anti-
Sm (p<0.001), anti-dsDNA (p=0.050), 
and anti-histone (p=0.048) (Table III).
Factors inﬂuencing time to 
cSLE diagnosis
The ECLAM score was inversely asso-
ciated with time to diagnosis (p<0.001, 
Spearman’s rho -0.397). None of the 
other tested factors showed an associa-
tion with time to diagnosis, including 
age, gender, distance from the near-
est tertiary referral centre, or clinical 
symptoms (Table IV).
Discussion
This is the ﬁrst in-depth analysis of 
clinical and laboratory manifestations 
of cSLE in Croatian children, a pre-
dominantly Caucasian population. The 
results indicate that cSLE features are 
similar to those reported in other coun-
tries, and by the time of diagnosis cSLE 
involved multiple organ systems. Of all 
clinical, laboratory, and demographic 
characteristics we examined, only the 
ECLAM score was (inversely) asso-
ciated with this interval. Our ﬁndings 
highlight the need for early diagnosis 
not only in children with very active 
disease, but also in children presenting 
with just few symptoms.
The annual incidence rate of cSLE ﬂuc-
tuated between 1 and 15 per million 
children at risk during the 20-year study 
period, which is comparable to 2.2 and 
2.8 per million reported for Canada (5, 
7, 21), and 9 per million for Finland (6). 
As it was shown in Figure 1, there was 
a signiﬁcant increase of the annual inci-
dence rate starting with the high peak in 
year 2004. This increasing trend could 
be explained by the introduction of rou-
tine antibody screening in children sus-
pected of cSLE: starting with the year 
2004, all sera positive by IIF were fur-
ther tested for auto-antibodies speciﬁc 
for SLE. In addition, primary care phy-
sicians probably became more aware of 
paediatric rheumatology diseases and 
more sensitive to cSLE symptoms.
The median interval between symp-
tom onset and cSLE diagnosis was 2 
months in our study, which is shorter 
than the 3.5–60 months reported in 
studies in Iran, South Africa, and even 
developed countries like France, Spain 
and the UK (3, 7, 8, 22-24). In fact, in 
our study, time to diagnosis was rela-
tively short even when initial symp-
toms were non-classical, whereas non-
classical symptoms in South Africa ex-
tended time to diagnosis to an average 
of 8 months (8). This may be because 
only 12% of our children presented 
with non-classical symptoms, which is 
much lower than the 30% reported in 
a French study (3) or 46% in a South 
African study (8).
In an effort to identify factors inﬂuenc-
ing time to diagnosis, we tested nu-
merous clinical, laboratory and demo-
Table III. Association of speciﬁc symptoms with auto-antibodies or patient location in 81 
Croatian children with juvenile systemic lupus erythematosus*.
 
Symptoms / Signs
Skin and mucose • • • <0.001 • • • • •
Raynaud’s phenomenon • • • • 0.009 • 0.051 • •
Neuropsychiatric <0.001 0.003 0.011 • • • • • •
Lupus nephritis • 0.002 • • • • • • •
Abdominal • • • • • • 0.013 • •
Antiphospholipid syndrome • 0.003 • 0.001 • • • • •
Thrombocytopenia • • • • • • 0.039 0.002 •
Pancytopenia • • • • • • 0.037 0.002 •
         
Patient location • <0.001 0.050 • • 0.048 • • -----
*Children (n=81) were divided into two groups based on the presence/absence of symptoms, and the 
levels of each protein were compared between the groups. Signiﬁcant differences between the two 
groups are indicated with the corresponding p-value, whereas non-signiﬁcant differences are repre-
sented with a dot (t-test for independent samples). A similar approach was used to compare boys with 
girls and to compare children in continental areas with children in Mediterranean areas.
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graphic factors. Of all factors tested, 
only one was associated with time to 
diagnosis: the ECLAM score was in-
versely associated with this interval, 
with weak power of the association 
(Table IV). A study of 257 children of 
Caribbean/African and Asian ethnicity 
in the UK found both lupus nephritis 
at presentation and the type of refer-
ring physician to be strong independ-
ent predictors of time to diagnosis 
(24). However, our data did not show 
an association between the presence of 
lupus nephritis and time to diagnosis. 
This difference may be due to the fact 
that in the UK study, shorter time to di-
agnosis was confounded with African 
ethnicity, which was also a predictor of 
time to diagnosis, since lupus nephritis 
occurs more often, at earlier ages and 
with greater severity in African adults 
and children with cSLE (25, 26). Con-
versely, people of European ancestry 
are “protected” from renal disease in 
SLE (27). We could not assess whether 
an association existed between the type 
of referring physician and time to diag-
nosis in our study population because 
these data were not recorded for most 
of our patients. Nevertheless, we do 
know that some children were referred 
by a general practitioner and the others 
by a paediatrician, so it would be inter-
esting to look for differences in time to 
diagnosis depending on the speciality 
of referring physician in future work.
Several additional factors may have 
contributed to extended time to diagno-
sis in our study. One possibility is mul-
tiple referrals. Approximately 80% of 
children in our study were from outside 
Zagreb and surrounding areas, mean-
ing that they probably went through 
a “multi-referral pathway” in which 
they were referred ﬁrst to a local sec-
ondary care centre, and then to one of 
the tertiary referral centres involved in 
our study, where they were ultimately 
diagnosed with cSLE. Usually, each of 
these steps requires making an appoint-
ment up to several weeks ahead. The 
remaining children were from Zagreb 
and surrounding areas, so they were 
probably referred in a single step to the 
tertiary centre there. Other factors that 
may have postponed diagnosis could be 
socioeconomic: less-educated, younger 
parents living in rural areas, with more 
than one child may not be aware of 
cSLE signs in their child, or may not 
take them seriously enough for a longer 
period of time. These aspects should be 
included in future work to gain a more 
complete picture of factors inﬂuencing 
time to diagnosis.
The median time of ﬁrst in-hospital 
evaluation in tertiary care centre was 
66 days. This appears very long, but it 
was mostly inﬂuenced by long admis-
sion times before 2004: namely, with 
the development of paediatric rheuma-
tology in Croatia, in recent years hos-
pital admission time of children with 
cSLE is has shortened.
Two children in our study died during 
initial assessment in the tertiary referral 
centre, one because of catastrophic an-
tiphospholipid syndrome and the other 
because of terminal renal failure. Even 
though the boys who died were aged 
7 and 8 yr, we found no difference in 
major organ involvement between chil-
dren younger and older than 14, which 
was the median age of cSLE onset in 
our study. These ﬁndings contrast with 
those of a US study that reported that 
younger children required more aggres-
sive treatment and more admissions to 
the paediatric intensive care unit (28). 
Although the two deaths in our study 
were boys, we found no signiﬁcant dif-
ference between girls and boys in the 
number of major organs involved or in 
the clinical and laboratory presentation 
of cSLE. This is in contrast with a Bra-
zilian study that reported male gender 
to be an independent factor associated 
with death (29).
After the ﬁrst in-hospital evaluation 
in the tertiary care centre, all chil-
dren were subsequently seen by the 
paediatric rheumatologist in regular 
check-ups, but only six children were 
re-admitted because of one or more 
relapses. Unfortunately, these are the 
data for paediatric tertiary care centres 
only, but we do not have the data about 
the admission because of cSLE relaps-
es in secondary care hospital or adult 
rheumatology wards (after the patients 
turned 18), because follow-up of cSLE 
patients was not within the scope of 
this study.
Although the children in our study pre-
sented clinical and laboratory features 
of cSLE similar to those of children 
in other countries (3, 7, 21-23, 30-
34), they showed some differences. 
Croatian children presented most fre-
quently with musculoskeletal symp-
toms, while children in numerous other 
studies mostly had skin-related symp-
toms (3, 7, 21, 30, 31) or constitutional 
symptoms (23, 32, 33). In addition, 
Croatian children experienced lung, 
neuropsychiatric, and non-classical 
symptoms less frequently than the chil-
Table IV. Analysis of factors inﬂuencing time to cSLE diagnosis in 81 Croatian children.
Variable p-value* (Spearman’s rho)
Distance from the nearest tertiary paediatric centre 0.611 (-0.063)
Patient’s age 0.467 (-0.090)
European Consensus Lupus Activity Measurement (ECLAM) score <0.001 (-0.397)
 p-value†
Gender 0.289
Clinical symptoms and signs 
    Constitutional 0.327
    Musculoskeletal 0.392
    Skin and mucose 0.205
    Heart 0.668
    Lung 0.539
    Vascular 0.749
    Raynaud’s phenomenon 0.973
    Immunological 0.601
    Neuropsychiatric 0.693
    Renal 0.501
    Lupus nephritis 0.433
    Abdominal 0.569
*Rank correlation test; †t-test for independent samples.
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dren in other studies (3, 8, 21-24, 30-
32, 24). While we observed a diversity 
of non-classical symptoms in 12% of 
children, such as torticolis, oedemas in 
various locations, sepsis, icterus, and 
chorea with ataxia, dysarthria and dys-
phonia, in the French study one third 
of children presented with no-classical 
symptoms, predominantly abdominal 
(3). This difference may indicate that 
Croatian physicians are less sensitive 
to abdominal symptoms when certain 
other symptoms are present.
Prevalence of renal involvement and 
renal failure at cSLE presentation in 
Croatian children were comparable to 
prevalence found in numerous other 
studies (3, 8, 15¸ 21, 30-34).
The fact that more than a third children 
in our study had other co-morbidites 
usually not found in cSLE patients 
(e.g. autoimmune thyroiditis, autoim-
mune hepatitis, seronegative JIA, Sjö-
gren disease coeliac disease) may be 
in concordance with ongoing debate 
“whether SLE may be considered not 
as a single disease, but rather as a sin-
gle syndrome, which deﬁnes by a set 
of signs, symptoms, or phenomena that 
occur together and suggest a particular 
abnormality“ (35). Also, it would be 
interesting to explore presence of or-
gan-speciﬁc auto-antibodies in children 
with other autoimmune diseases, such 
as autoimmune thyroiditis or hepatitis, 
coeliac disease, in Croatian children 
with cSLE, as it has been recently done 
by Aikawa et al. (36), but given the ret-
rospective nature of this study, this was 
not possible.
Since many children with cSLE have 
multiple organ systems involved and 
subsequently lowered quality of life, 
an effort should be made to develop 
and examine the usefulness of track-
ing the quality of life of cSLE patients 
with multidimensional instruments like 
the Juvenile Arthritis Multidimensional 
Assessment Report does (37): a similar 
multidimensional tool for cSLE would 
take into account the perspectives of 
the patient and parents, unlike the 
British Isles Lupus Assessment Group 
(BILAG) index (38) or the Systemic 
Lupus Erythematosus Disease Activity 
Index (SLEDAI) (39), which both re-
ﬂect only physician’s assessment.
The most frequent autoantibodies in 
Croatian children were against histones, 
SS-B Smith and RNP antigen, while the 
predominant auto-antibodies in other 
studies were against dsDNA (3, 7, 21-
24, 30-32, 34). Almost all autoantibod-
ies were associated with the presence 
of at least one clinical or laboratory 
manifestation of cSLE or patient loca-
tion. Similarly, almost all clinical and 
laboratory manifestations were associ-
ated with the presence of at least one 
autoantibody, and some of them with 
more than one. Unfortunately, only few 
studies have investigated the associa-
tion of clinical and laboratory features 
of cSLE with the presence of speciﬁc 
auto-antibodies. In our study, lupus ne-
phritis was associated with high levels 
of only anti-Sm antibody, while in a Ca-
nadian study (21) it was associated with 
high levels of anti-Sm, anti-RNP, and 
anti-CL IgM, and in a Belgian study 
(32) it was associated with high levels 
of anti-dsDNA antibodies.
Frequencies of clinical and laboratory 
features (including skin symptoms) did 
not vary signiﬁcantly between Croatian 
children living in continental and Med-
iterranean climates.
This result was unexpected, given the 
strong evidence implicating UV-B ra-
diation as a trigger in cSLE onset (1). 
This discrepancy may reﬂect the fact 
that Croatia is a small country spread-
ing over only 2.5 degrees of latitude.
Except of this geographical limitation 
and its retrospective nature, this study 
has several other limitations: ﬁrst: it in-
volved only 81 patients; second: just a 
proportion of children were tested for 
auto-antibodies – some of the associa-
tions might have been different in larg-
er cohorts; and third: we compared our 
results with the result of other studies 
that might have detected antibodies us-
ing methods other that ELISA (e.g. im-
munoblotting, RIA, and multiplex and 
array technologies). In general, results 
obtained with the different methods 
correlate well, but discrepancies may 
arise due to different source of antigen, 
presentation of the antigen to the anti-
body, reaction conditions, or the avid-
ity of the antibodies detected (40-42). 
Nevertheless, since the results in this 
study are similar to the results in other 
studies, we believe that the aforemen-
tioned limitations do not preclude us 
from drawing valid conclusions.
Even though diagnosis occurred with-
in 2 months of symptom onset in our 
study, more than a half of Croatian 
children had involvement of more than 
3 organ systems by the time of diagno-
sis. During the months before correct 
diagnosis, most children with arthral-
gia/arthritis adapted their behaviour to 
avoid using affected joints, which led 
to restricted movement in those joints, 
and in some cases to shortening of 
tendons with contractures. Moreover, 
more than half of the children in our 
study developed lupus nephritis by the 
time of diagnosis.
Conclusion
This work highlights the need for fur-
ther research to identify other factors, 
in addition to ECLAM score, that may 
be related to extended time to diagno-
sis. Such studies may help clinicians to 
detect children with cSLE early in the 
course of the disease, when the disease 
is still mild or fewer organ systems are 
involved.
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